Non-invasive tests in metabolic dysfunction-associated steatotic liver disease: the LITMUS prospective multicentre diagnostic accuracy study.

SomaSignal is linked to the best diagnostic accuracy for at-risk MASH in biopsy-confirmed MASLD, achieving an AUC of 0·83 (95% CI 0·80–0·85).

• Why it matters: Regulatory-approved MASLD therapies increase the need for accurate, non-invasive biomarkers to identify MASH severity and fibrosis stage, enabling earlier diagnosis and better trial enrolment.
• What they did: In a prospective multicentre diagnostic accuracy study across 13 European countries and the USA, 1590 adults with biopsy-confirmed MASLD were assessed with 12 single markers and 18 multimarker panels against centrally scored histology.
• The result: For advanced fibrosis and cirrhosis, multimarker strategies met or exceeded performance thresholds, including SomaSignal (AUC 0·92) and FibroMeter-VCTE (AUC 0·94), and two-step gamma-glutamyl transferase approaches met the MAC.

AI summary of the abstract · may contain errors · not medical advice · read the paper.